Cargando…

Strategies to enhance CAR-T persistence

Chimeric antigen receptor T (CAR-T) cell therapy has significantly improved the life expectancy for patients with refractory or relapse B cell lymphoma. As for B cell acute lymphoblastic leukemia (B-ALL), although the primary response rate is promising, the high incidence of early relapse has caused...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yue, An, Lingna, Huang, Ruihao, Xiong, Jingkang, Yang, Haoyu, Wang, Xiaoqi, Zhang, Xi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685914/ https://www.ncbi.nlm.nih.gov/pubmed/36419115 http://dx.doi.org/10.1186/s40364-022-00434-9

Ejemplares similares

Ginsenoside Rg1 improves anti-tumor efficacy of adoptive cell therapy by enhancing T cell effector functions
por: Liu, Yue, et al.
Publicado: (2023)

Facing challenges with hope: universal immune cells for hematologic malignancies
por: Wang, Yuqing, et al.
Publicado: (2023)

Strategies for enhancing CAR T cell expansion and persistence in HIV infection
por: Rothemejer, Frederik Holm, et al.
Publicado: (2023)

Recent advances in CAR-T cell engineering
por: Huang, Ruihao, et al.
Publicado: (2020)

Improving CAR T-Cell Persistence
por: Pietrobon, Violena, et al.
Publicado: (2021)

CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022
por: Huang, Ruihao, et al.
Publicado: (2023)

Current status and prospects of hematopoietic stem cell transplantation in China
por: Wang, Xiaoqi, et al.
Publicado: (2022)

CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence
por: Wei, Wei, et al.
Publicado: (2023)

Genetic Modification Strategies to Enhance CAR T Cell Persistence for Patients With Solid Tumors
por: DeRenzo, Christopher, et al.
Publicado: (2019)

Clinical Strategies for Enhancing the Efficacy of CAR T-Cell Therapy for Hematological Malignancies
por: Liu, Qianzhen, et al.
Publicado: (2022)

P522: OFF-THE-SHELF CD33 CAR-NK CELL THERAPY FOR RELAPSE/REFRACTORY AML: FIRST-IN-HUMAN, PHASE I TRIAL
por: Huang, Ruihao, et al.
Publicado: (2023)

Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T
por: Shiqi, Li, et al.
Publicado: (2023)

Enhancing T cell persistence of CAR-redirected T cells in solid tumors
por: Guedan, Sonia, et al.
Publicado: (2014)

Engineering CAR T cells for enhanced efficacy and safety
por: Wu, Yiqian, et al.
Publicado: (2022)

IL-24 armored CAR19-T cells show enhanced antitumor activity and persistence
por: Hu, Qian, et al.
Publicado: (2021)

Engineering CAR-T cells
por: Zhang, Cheng, et al.
Publicado: (2017)

Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
por: Sun, Shangjun, et al.
Publicado: (2018)

Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy
por: Yang, Guancui, et al.
Publicado: (2022)

PD-1 blocking strategy for enhancing the anti-tumor effect of CAR T cells targeted CD105
por: Wang, Xi, et al.
Publicado: (2023)

Development of CAR-T Cell Persistence in Adoptive Immunotherapy of Solid Tumors
por: Fan, Jiaqiao, et al.
Publicado: (2021)

Challenges and optimal strategies of CAR T therapy for hematological malignancies
por: Zhang, Yajing, et al.
Publicado: (2023)

Exploring CAR-T Cell Therapy Side Effects: Mechanisms and Management Strategies
por: Zhang, Yugu, et al.
Publicado: (2023)

Emerging CAR T Cell Strategies for the Treatment of AML
por: Vishwasrao, Paresh, et al.
Publicado: (2022)

CAR models: next-generation CAR modifications for enhanced T-cell function
por: Abate-Daga, Daniel, et al.
Publicado: (2016)

New Strategies for the Treatment of Solid Tumors with CAR-T Cells
por: Zhang, Hao, et al.
Publicado: (2016)

CAR-T cells for Colorectal Cancer: Target-selection and strategies for improved activity and safety
por: Li, Huali, et al.
Publicado: (2021)

Recent advances in ocular graft-versus-host disease
por: Cheng, Xianjing, et al.
Publicado: (2023)

CAR-T Cell Performance: How to Improve Their Persistence?
por: López-Cantillo, Gina, et al.
Publicado: (2022)

Strategies for Improving the Efficacy of CAR T Cells in Solid Cancers
por: Kyte, Jon Amund
Publicado: (2022)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward
por: Li, Jian, et al.
Publicado: (2018)

Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming
por: Wang, Yao, et al.
Publicado: (2021)

Potential strategies against resistance to CAR T-cell therapy in haematological malignancies
por: Cai, Qing, et al.
Publicado: (2020)

CAR‐T cell therapy for lung cancer: Potential and perspective
por: Chen, Long, et al.
Publicado: (2022)

Case Report: Sirolimus Alleviates Persistent Cytopenia After CD19 CAR-T-Cell Therapy
por: Xing, Limin, et al.
Publicado: (2021)

CAR-T cell therapy: current limitations and potential strategies
por: Sterner, Robert C., et al.
Publicado: (2021)

Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy
por: Bangayan, Nathanael J., et al.
Publicado: (2023)

Challenges and strategies of clinical application of CAR-T therapy in the treatment of tumors—a narrative review
por: Li, Weijing, et al.
Publicado: (2020)

Engineering switchable and programmable universal CARs for CAR T therapy
por: Liu, Delong, et al.
Publicado: (2019)

P1275: SAFETY AND EFFICACY OF HUMAN AMNIOTIC EPITHELIAL STEM CELLS EYE DROP IN OCULAR CHRONIC GRAFT-VERSUS-HOST DISEASE
por: Cheng, Xianjing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2qaru3fq46as7jdvbh0a44fmll